Abstract
Objectives: To assess the effect of glibenclamide and metformin on serum uric acid level in patients with type ٢ diabetes. Study design: Case control study. Subjects and Methods: This study was conducted from March ٢٠٠٩ to January ٢٠١٠. Fasting blood sugar and serum uric acid level were measured in patients suffering from type- ٢ diabetes mellitus who were referred to Al-Wafa Diabetic Center in Mosul City. Group ١: ٣٢ patients on glibenclamide therapy, group ٢: ٤٢ patients on metformin therapy and group ٣: ٤٢ patients on combination therapy, group ٤: ٣٢ patients on restricted diet, and ٢٣ apparently healthy volunteers, were taken as a control group. Results: The study showed a significant increase in the serum uric acid level of the diabetic patients as compared with the control. Glibenclamide and/or metformin showed no significant difference in the serum uric acid level in patients with type ٢ diabetes mellitus. Conclusion: Glibenclamide and/or metformin had no significant effect on serum uric acid level in patients with type ٢ diabetes mellitus.
